{"organizations": [], "uuid": "f74a8c6fcb2716ae5e94126cb0dbf3097b79a379", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180521.html", "section_title": "Archive News &amp; Video for Monday, 21 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-glaxosmithkline-receives-us-approv/brief-glaxosmithkline-receives-us-approval-of-arnuity-ellipta-for-use-in-children-from-5-years-old-who-suffer-from-asthma-idUSFWN1SS0PF", "country": "US", "domain_rank": 408, "title": "BRIEF-GlaxoSmithKline Receives US Approval Of Arnuity Ellipta For Use In Children From 5 Years Old Who Suffer From Asthma", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 1.0, "site_type": "news", "published": "2018-05-22T00:03:00.000+03:00", "replies_count": 0, "uuid": "f74a8c6fcb2716ae5e94126cb0dbf3097b79a379"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-glaxosmithkline-receives-us-approv/brief-glaxosmithkline-receives-us-approval-of-arnuity-ellipta-for-use-in-children-from-5-years-old-who-suffer-from-asthma-idUSFWN1SS0PF", "ord_in_thread": 0, "title": "BRIEF-GlaxoSmithKline Receives US Approval Of Arnuity Ellipta For Use In Children From 5 Years Old Who Suffer From Asthma", "locations": [], "entities": {"persons": [], "locations": [{"name": "us", "sentiment": "none"}], "organizations": [{"name": "us approval of arnuity ellipta", "sentiment": "negative"}, {"name": "glaxosmithkline plc", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "gsk", "sentiment": "negative"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 21 (Reuters) - GlaxoSmithKline PLC:\n* GSK RECEIVES US APPROVAL OF ARNUITY ELLIPTA FOR USE IN CHILDREN FROM 5 YEARS OLD WHO SUFFER FROM ASTHMA\n* RECEIVED APPROVAL FROM US FDA FOR USE OF ARNUITY ELLIPTA (FLUTICASONE FUROATE) FOR MAINTENANCE TREATMENT OF ASTHMA IN CHILDREN FROM AS YOUNG AS 5 YEARS Source: bit.ly/2KIfvII Further company coverage: (Reuters.Briefs@thomsonreuters.com)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "https://bit.ly/2KIfvII", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-22T00:03:00.000+03:00", "crawled": "2018-05-22T19:20:57.009+03:00", "highlightTitle": ""}